In recessive dystrophic epidermolysis bullosa, the MissionEB phase 3 study tested intravenous infusions of umbilical cord-derived mesenchymal stromal cells in 37 children. Alongside the clinical data, a qualitative sub-study gathered the voices of parents and young patients — and reveals something that standard scores couldn’t measure.
What is epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disease caused by mutations in the type VII collagen gene. This protein acts as an anchoring system between the epidermis, the outer layer of skin, and the underlying dermis.
When the anchors are missing, the two layers slide against each other: even minimal friction can cause blisters, open wounds, and scarring. It’s this fragility that gives rise to the name these children are known by — butterfly children.
The consequences of epidermolysis bullosa go beyond the skin. Scarring can lead to limb contractures and fusion of the fingers; lesions in the mouth and esophagus make eating difficult; and the risk of developing skin cancers at a young age is high. A concise clinical summary of the condition is available on Orphanet, the European reference portal for rare diseases.
Today there is no definitive cure. Management centers on wound cleaning, specialized dressings, and symptom control — a commitment that can take up many hours a day and weighs on the entire family.
The MissionEB study
MissionEB is a phase 3 study — the final stage of clinical trials before potential approval — conducted with a rigorous design:
- randomized: random assignment to groups;
- double-blind: neither patients nor doctors knew who was receiving the active treatment;
- placebo-controlled;
- crossover: each child received both treatments nine months apart, allowing comparison within the same subject.
37 children took part. The treatment consisted of intravenous infusions of UC-MSCs, mesenchymal stromal cells from cord tissue, known for their ability to modulate the immune response and support tissue repair. Ongoing studies in this research area can be found on ClinicalTrials.gov.
Why a qualitative sub-study was added
In rare diseases, patient numbers are by definition small, which makes it difficult to reach statistical significance on quantitative endpoints. MissionEB’s numerical data were encouraging but not always easy to interpret.
For this reason, researchers added a qualitative sub-study: in-depth interviews with 10 parents and 6 children, conducted at two different points during the trial. The goal was to capture the lived experience — not to replace the numbers, but to complement them.
Epidermolysis bullosa: what families reported
Less pain, much less itching. The most frequently reported benefit after infusion was reduced pain and itching. Itching in particular was described by families as more debilitating than the pain itself: it prevents sleep and triggers new lesions from scratching. One child said it used to hurt during bath time, but that hadn’t been happening lately.
Faster healing, fewer dressing changes. Many families reported that sores which had previously stayed open for weeks began to close within days. The practical consequence is fewer dressing changes: less suffering, more time for normal life.
More energy and appetite. An unexpected finding. Epidermolysis bullosa carries an extremely high metabolic cost, as the body is constantly engaged in skin repair. With fewer active wounds and less inflammation, several children began eating better and gaining weight.
Social life. This is the change families identified as most significant. One child described being able to run and play outside with friends much more than before.
The most striking detail
Ten out of thirteen participants who completed both interviews were able to correctly identify which phase they had received the cells in and which was the placebo, based solely on symptom changes. In a double-blind study, the perceived difference was clear enough to be evident to those living with the disease every day.
Researchers nonetheless remain cautious and note possible placebo effects: the hope tied to trial participation, but also the fact that during the study children received more intensive and frequent care — nutritional monitoring, rapid treatment of infections, correction of iron deficiencies — factors that alone can improve the condition.
Practical difficulties
The main problem reported was venous access: in children with epidermolysis bullosa, veins are hard to find and the skin is extremely fragile, so cannula insertion was often a source of stress and tears. One parent also reported a curious and already-known side effect: a “sweet corn” smell noticed right after infusion, linked to a preservative used in cell preparation.
Why qualitative research matters
Standard tools used to measure the severity of epidermolysis bullosa — such as the EBDASI index, based on the extent of wounds and scarring — may not be sensitive enough to capture changes that are small in numbers but enormous in real life.
For a child, sleeping through a whole night without scratching, or eating an apple without hurting their mouth, is an outcome no skin-surface score can represent. This is exactly what qualitative research is for: keeping drug development centered on the patient.
Conclusions
All the parents interviewed said they would repeat the treatment, even for minimal benefits. One of them explained that even a 1% improvement means a great deal to them.
MissionEB does not offer a definitive cure for epidermolysis bullosa, nor do the authors claim it does. But it does point in a direction: repeated UC-MSC infusions could become a maintenance therapy able to reduce the disease’s daily burden.
Important note: The applications described belong to the field of clinical research and do not constitute approved therapies available in current practice. No information reported here should be understood as medical advice. For any clinical evaluation, please consult your physician.
Why SSCB follows these studies
The UC-MSCs used in MissionEB come from umbilical cord tissue — the same source SSCB has been cryopreserving since 2005 alongside cord blood and placenta, a distinction we explore further in our comparison of cord blood, cord tissue, and placenta.
Over 550 clinical trials are currently active on perinatal stem cells, a number that explains why the quality and traceability of the stored sample have become a requirement rather than a detail. SSCB is the only Swiss biobank accredited by FACT-NetCord: you can find the full picture in our deep dive on standards and accreditations.
Want to follow updates on rare disease research and regenerative medicine? Subscribe to the SSCB scientific newsletter.
Source: Biggs K, Ditta S, Bageta ML, et al. Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial. Orphanet J Rare Dis. 2026;21(1):272. doi:10.1186/s13023-026-04350-1
